DoW Breast Cancer, Transformative Breast Cancer Consortium Award

<p><strong>Summary: </strong>The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Award supports collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer. Applications must propose a synergistic, highly integrated, multidisciplinary and multi-institutional consortium of leading scientists, clinicians and breast cancer consumer advocates that will address a major problem in a way that a single investigator or group could not accomplish. The consortium’s collaborative efforts must make a transformative impact in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. If the application addresses a different fundamental issue, the application must couple it with at least one of the overarching challenges.</p><p><strong>Distinctive Features: This funding mechanism allows for up to five Principal Investigators (PIs) which includes the Consortium Director and three or four Project Team PIs. Applications must include at least one breast cancer consumer advocate per project team. </strong>Only the Consortium Director will submit a pre-application, but all PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Consortium Director and Project Team PIs) applications by the full application deadline may result in administrative withdrawal.</p>